Ahngook Pharmaceutical said Tuesday that it signed a stock purchase agreement with Dimedi Korea last Friday.

The acquisition supports Ahngook Pharm's goal to advance its “Business Diversification (H&B)”—a key part of its “2030 New Vision” strategy—and maintains its growth investment approach in line with the recently formed Mirae Asset Ahngook New Growth Investment Fund No. 1.

Dimedi Korea is a healthcare company that develops and manufactures sleep tech and lifestyle medical devices based on shape-memory polymer (SMP) technology. Its main brands include GOYO and GOYOZAM mouthpieces, COCOPICK nasal dilator, Bodyrang silver care line, and GOHEX sports mouthguard.

Through this acquisition, Ahngook Pharm will strengthen its health tech and H&B portfolio, while Dimedi Korea will use Ahngook's national sales network and brand credibility to expand distribution channels and maximize growth synergies.

“Ahngook Pharmaceutical is constantly seeking new growth opportunities even within a changing market environment,” Ahngook Pharmaceutical CEO Park In-cheol said. “With this acquisition, we will continuously expand into new business areas, including health tech and H&B, diversify our revenue base through M&A and investments, and strengthen our future growth engines.”